摘要
目的探讨小剂量丙戊酸镁缓释剂治疗持续性躯体形式疼痛障碍的临床疗效及安全性。方法选择持续性躯体形式疼痛障碍患者60例,随机分为研究组和对照组,每组30例,研究组给予文拉法辛联合小剂量丙戊酸镁缓释剂治疗,对照组采用文拉法辛治疗,比较两组患者的临床效果。结果研究组总有效率显著高于对照组(P<0.05)。治疗后两组HAMD评分、疼痛评分较治疗前下降,差异有统计学意义(P<0.01);研究组HAMD评分及疼痛评分低于对照组,差异有统计学意义(P<0.01)。研究组不良反应量表评分为(2.0±0.6)分,对照组为(1.9±0.5)分,两组比较差异无统计学意义(P>0.05)。结论在文拉法辛治疗基础上给予小剂量丙戊酸镁缓释剂治疗能够显著提高持续性躯体形式疼痛障碍临床疗效,且未增加不良反应,值得临床推广。
Objective To explore the clinical efficacy and safety of small doses of magnesium valproate sustained re-lease formulation in treatment of persistent somatoform pain disorder. Methods 60 cases of persistent somatoform pain disor-der were divided into study group and control group randomly , 30 cases in each group. Study group were treated with Venlafax-ine combined with small doses of magnesium valproate sustained release formulation , and control group were treated with Ven-lafaxine. Clinical efficacy of two groups were compared. Results Total efficiency of study group was higher than that of control group （P〈0.05）. After treatment, HAMD and pain scores of two groups decreased （P〈0.01）, HAMD and pain scores of study group were lower than those of control group （P〈0.01）. Adverse reactions rating scale of study group was 2.0±0.6, and that of control group was 1.9±0.5, which showed no significant difference between the two groups （P〉0.05）. Conclusion Venlafax-ine combined with small doses of magnesium valproate sustained release formulation in treatment of persistent somatoform pain disorder can improve the clinical efficacy without increasing adverse reactions , which is worthy of clinical promotion.
出处
《中国现代医药杂志》
2015年第5期27-29,共3页
Modern Medicine Journal of China
关键词
丙戊酸镁缓释剂
文拉法辛
持续性躯体形式疼痛障碍
Magnesium valproate sustained release formulation
Venlafaxine
Persistent somatoform pain disorder
